Non-Invasive Prenatal Testing (NIPT) with microdeletions is an advanced screening method that analyzes fetal DNA circulating in a pregnant woman’s blood. This test is designed to detect not only common chromosomal abnormalities, such as fetal chromosomal aneuploidy, but also smaller genetic deletions known as microdeletions. CapitalBio’s NIPT Plus is a state-of-the-art solution that offers comprehensive screening for both aneuploidies and microdeletions, providing healthcare providers with reliable and accurate results.
What is the Genetic Disorder Microdeletion?
A genetic disorder microdeletion occurs when a small segment of a chromosome is missing. These deletions can lead to a variety of developmental and health issues, depending on the specific genes that are affected. Microdeletions can result in conditions such as DiGeorge syndrome, Prader-Willi syndrome, and Angelman syndrome. CapitalBio’s NIPT Microdeletions test is designed to identify these small but significant genetic anomalies early in pregnancy, allowing for timely medical intervention and planning.
What are Aneuploidies?
Aneuploidies are genetic conditions where there is an abnormal number of chromosomes in a cell. Instead of the typical 46 chromosomes, an individual with aneuploidy may have one extra or one missing chromosome. This imbalance can lead to various developmental and health issues. Common examples of aneuploidies include Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). CapitalBio’s Fetal Chromosomal Aneuploidy test is designed to detect these abnormalities with high accuracy, providing essential information for prenatal care.
What are the 4 Types of Aneuploidy?
Monosomy: This occurs when there is a missing chromosome in a pair. For example, Turner syndrome is a condition where a female has only one X chromosome instead of two.
Trisomy: This is the presence of an extra chromosome. Down syndrome (trisomy 21) is the most well-known example, where there is an extra copy of chromosome 21.
Tetrasomy: This rare condition involves the presence of two extra chromosomes. An example is tetrasomy 18p, where there are four copies of the short arm of chromosome 18.
Nullisomy: This extremely rare condition involves the absence of both chromosomes in a pair. Nullisomy is usually lethal and not compatible with life.
CapitalBio’s NIPT Plus is capable of detecting these various types of aneuploidies, providing comprehensive screening for expectant parents.
What are Microdeletions in Pregnancy?
Microdeletions in pregnancy refer to small missing segments of DNA within a chromosome that can lead to genetic disorders. These deletions are often too small to be detected by traditional karyotyping methods. However, they can have significant impacts on a child’s development and health. Conditions such as DiGeorge syndrome (22q11.2 deletion) and Williams syndrome (7q11.23 deletion) are examples of disorders caused by microdeletions. CapitalBio’s NIPT Microdeletions test is specifically designed to identify these small but critical genetic changes, offering a more detailed and accurate prenatal screening option.
What is the Most Common Fetal Aneuploidy?
The most common fetal aneuploidy is Down syndrome, also known as trisomy 21. This condition occurs when there is an extra copy of chromosome 21, leading to developmental delays, intellectual disabilities, and various health issues. Down syndrome is the most frequently occurring chromosomal abnormality detected in prenatal screenings. CapitalBio’s Fetal Chromosomal Aneuploidy test is highly effective in identifying Down syndrome, along with other common aneuploidies, providing crucial information for expectant parents and healthcare providers.
Conclusion
CapitalBio’s NIPT Plus offers a comprehensive solution for prenatal screening, detecting both fetal chromosomal aneuploidy and microdeletions with high accuracy. By understanding the complexities of genetic disorders such as aneuploidies and microdeletions, healthcare providers can offer better care and support to expectant parents. CapitalBio’s advanced testing methods ensure that critical genetic information is available early in pregnancy, allowing for informed decision-making and improved outcomes. Choose CapitalBio for cutting-edge, reliable prenatal diagnostics.
What Are the Main Processes of DNA Microarray Technology?March 8, 2023The principle of DNA microarray technology is to integrate gene probes with known sequences onto a solid surface. A large number of labeled nucleic acid sequences from the tested biological cells or t...view
Knowledge About Transcriptome SequencingDecember 1, 2022In a broad sense, the transcriptome refers to the collection of all transcripts in a cell under a certain physiological condition, including messenger RNA, ribosomal RNA, transfer RNA and non-coding R...view
One Of The Most Common Birth Defects In The World Is Hearing LossJune 28, 2022One of the most common birth defects in the world is hearing loss. Every 1,000 babies are born with permanent hearing loss in one or both ears. Hearing loss can have a significant impact on a baby'...view
Chromosome Microarray (CMA) DetectionAugust 27, 2024Testing ContentDetection of 23 pairs of chromosomal aneuploidy and whole genome chromosomal abnormalities greater than 100kb.Testing MethodMicroarray Chip methodCMA ChipSample RequirementsVenous Blood...view